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Abstract
Background: Psychotic relapse leads to repeated hospitalization and negatively affects the clinical prognosis of the
patients. Information on prevalence of relapse among patients with psychotic disorders in Ethiopian setting is
scarce. This study aimed to assess the prevalence of relapse among patients with psychotic disorders attending
services in Jimma University Specialized Hospital (JUSH).
Methods: Data were collected using interviewer administered questionnaire. We used medication adherence rating
scale (MARS) to assess compliance to medication and abnormal involuntary movement scale (AIMS) to detect
medication side effects. Logistic regression analysis was used to identify independent predictors of psychotic relapse.
All variables with P-value <0.25 in the bivariate analyses were entered into multivariate logistic regression and variables
with P-value < 0.05 in the final model were declared to be significantly associated with the outcome variable.
Results: The prevalence of relapse among patients with psychotic disorder was 24.6 % (n = 95). Of this, 25.4 and 22.4 %
were males and females respectively. The odds of developing psychotic relapse among patients living with family was
72 % lower than that of patients living alone (aOR = 0.28, 95 % CI = 0.08, 0.93). The odds of developing psychotic
relapse among patients compliant to medication was 69 % lower than that of patients who were not compliant to
medications (aOR = 0.31, 95 % CI = 0.12, 0.80). The odds of developing psychotic relapse among patients having high
score on social support score was 48 % lower than that of patients who were compliant to medications (aOR = 0.52,
95 % CI = 0.28, 0.95). The odds of developing psychotic relapse among patients reporting to have sought religious
support was 45 % lower than that of patients who have not sought religious support (aOR = 0.55, 95 % CI = 0.31, 0.96).
On the other hand, the odds of developing psychotic relapse among participants who have experienced medication
side effects was 1.83 times higher when compared to those who have never experienced medication side effects
(aOR = 1.83, 95 % CI = 1.01, 3.31).
Conclusions: The high prevalence of relapse among patients with psychotic disorder needs special attention.
Clinicians need to pay attention to medication side effects the patient faces. Intervening noncompliance to medication
and appropriately managing medication side effects may help in preventing psychotic relapse that may result because
of non-compliance. The provision of counseling, psycho education, psycho social support may help patients in
improving compliance to medication and reducing psychotic relapse. Developing and strengthening community
based rehabilitation services should be emphasized as part of mental healthcare services.
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Background
Mental illness is among the prevalent non-communicable
diseases worldwide [1]. Mental health negatively affects
both the patient and the family members financially
and socially [2]. The stigma attached to schizophrenia
creates a vicious cycle of discrimination leading to so-
cial isolation, unemployment, drug abuse, long lasting
institutionalization or even homelessness, which fur-
ther decreases the chances of recovery. Families of
patients carry the burden of caring for patients
through restricted social activities and economic
problems [3]. Relapse costs a lot for patients and
their families and imposes a financial burden on hos-
pital and community services [4]. Costs for relapse
cases were four times higher than that of non-relapse
cases [5]. Relapse cases are associated with hospital
admissions. The cost of hospitalization contributes to
one- to two- third of the cost for the care of schizo-
phrenia [6]. Relapses may also lead the patients to
stay on medication for a longer period of time [7].
Relapse was associated with medication side effects
[8–11], substance use [12–15], long stay before initiat-
ing therapy [16–18] and comorbid medical or psychiatric
illness [19–21].
A study conducted in rural Ethiopia showed that,
families of patients diagnosed with schizophrenia had
spent $16.52 out-of-pocket and on average spent
3.12 (SD = 4.54) days of work due to care giving in
one month [22]. However, there is limited data on
prevalence of relapse and associated factors among
patients with psychotic disorders. Therefore, this re-
search aimed at assessing the prevalence of, and risk




This cross-sectional study was conducted in Jimma
University specialized hospital (JUSH), which is lo-
cated in southwestern part of Ethiopia 354 km far
from Addis Ababa. Jimma University specialized hos-
pital provides psychiatric services for inpatient and
outpatient services [23]. The outpatient psychiatry clinic
at JUSH was established in 1988. Data collection for this
research was conducted in November, 2013.
Sample size determination and sampling procedure
The sample size for the study was determined by as-
suming relapse rate of 50 % giving any particular out
come to be with in 5 % marginal error and 95 % con-
fidence interval of certainty (alpha = 0.05). Based on
this assumption, the actual sample size calculated for
this study was 386. All adult patients were invited to
participate in the study consecutively.
Data collection instrument
Data were collected using a structured interviewer ad-
ministered questionnaire on the following variables:
Relapse among patients with psychotic disorder
A structured interviewer administered questionnaire
containing a yes or no question was used to assess
relapse. We assessed relapse based on the DSM IV-TR
relapse definition criteria [24]. Patients were asked
about the numbers of relapses they had. In addition, we
reviewed their charts to identify the recorded numbers
of relapses.
Factors associated with relapse
Socio demographic factors: The structured
questionnaire contained questions on socio-
demographic and socio-economic status of the
patients (age, sex, marital status, and educational
level, and ethnicity, frequency of attending a place of
worship, occupation, income and living condition).
Medication related factors: We used medication
adherence scale (MARS) to assess adherence to
anti-psychotic medication [25]. Patients who
responded ‘no’ for questions numbers 1–6 and 9–10
and ‘yes’ for question numbers 7–8 were considered
as compliant. And those patients who responded ‘yes’
for question numbers 1–6 and 9–10 and ‘no’ for
question numbers 7–8 were considered as non-
compliant [26]. Also abnormal involuntary movement
scale (AIMS) was used to assess medication side
effects. The AIMS is considered as standard clinical
practice for patients receiving long term neuroleptic
drugs and it was applied by clinicians [27, 28].
Substance use disorders: We utilized CAGE (cudown,
annoyed, guilty and eye opener) to screen alcohol use
disorder. Two or more positive responses on CAGE
are indicative of alcoholism [29]. We used Drug
abuse screening test (DAST) to assess khat abuse
[30]. Khat is a leaf, which is one among psychoactive
substances and it is commonly used in East Africa
including Ethiopia [31, 32] The interpretation of
DAST is follows: a score of zero indicates absence of
substance abuse, 1–2 indicate low level of substance
abuse, 3–5 indicate moderate level of substance
abuse, 6–8 indicate substantial level of substance
abuse and 9–10 indicate severe level of substance
abuse. Those participants having moderate level of
substance abuse need referral to professionals [33–35].
Duration of untreated psychotic disorder and
Comorbidity: The participants were asked to indicate
the duration of time they stayed before they sought
therapy at modern health services after the onset
of the illness. In addition, we asked the places they
went before they sought services at modern health
institutions.
Fikreyesus et al. BMC Psychiatry  (2016) 16:354 Page 2 of 10
Social support: We measured social support using six
items. Each question had two parts. The first part is
about the number of individuals that participants
listed as a source of support and the second one is
their level of satisfaction [36].
Data collection procedures
The questionnaire was pretested on a sample equal to
5 % of the total sample size that were not part of the
main study. Data were collected by interviewing patients
with diagnosis of psychotic disorders coming to JUSH
psychiatry clinic for follow-up purposes. Three psychi-
atric nurses and two postgraduate students attending
their studies in masters program in integrated commu-
nity and clinical mental health (ICCM) collected the
data. Two students attending masters program in ICCM
and the principal investigator supervised the data collec-
tion. Before the data collection, a two-days training was
given for the data collectors and suppervisors. The train-
ing included detailed information on how to collect data,
how to score the different scales used in the study and
how to perform AIMS. The supervisor monitored data
quality and checked all questionnaires for completeness.
Data analysis
Data were checked for completeness, and were entered
into Epi-Data version 3.1. After double entry verification,
the data were exported to SPSS (statistical package for
social science) version 20 for analyses.
The dependent variable (relapse) and independent vari-
ables (predictors) were entered into bivariate logistic regres-
sion in order to determine statitical association between
dependent and independent variables. All variables associ-
ated with the dependent variable with p-value less than
0.25 in the bivariate analyses of the binary logistic regres-
sion were entered into multivariate models of the logistic
regression by enter method in order to identify interaction
between variables and to control for potential confounders.
Table 1 Socio-demographic characteristics of patients with
psychotic disorders, Jimma University Specialized Hospital,
Ethiopia, 2013 (n = 386)
Socio demographic characteristics Number (percent)
Sex
Male 279 (72.3 %)
Female 107 (27.7 %)
Age
18–24 79 (20.5 %)
25–34 186 (46.2 %)
35–44 82 (21.2 %)
45–54 28 (7.3 %)
55–68 11 (2.8 %)
Religion
Orthodox 97 (25.1 %)
Muslim 234 (60.4 %)
Protestant 51 (13.2 %)
Catholic 1 (0.3 %)
Other* 3 (0.8 %)
Frequency
Frequent 170 (44 %)
Sometimes 196 (50.8 %)
Never 20 (5.2 %)
Ethnicity
Oromo 239 (61.9 %)
Amhara 66 (17.1 %)
Gurage 19 (4.9 %)
Kaffa 26 (6.7 %)
Dawro 20 (5.2 %)
Yem 5 (1.3 %)
Other** 11 (2.8 %)
Marital status
Single 179 (46.4 %)
Married 188 (48.7 %)
Divorced 11 (2.88 %)
Separated 2 (0.5 %)
Widowed 6 (1.6 %)
Educational
Illiterate 50 (13 %)
Primary 176 (45.6 %)
Secondary 96 (24.9 %)
Tertiary 64 (16.6 %)
Occupation
Unemployed 112 (29 %)
gov't employee 87 (22.5 %)
Merchant 26 (6.7 %)
Table 1 Socio-demographic characteristics of patients with
psychotic disorders, Jimma University Specialized Hospital,
Ethiopia, 2013 (n = 386) (Continued)
Private 29 (7.5 %)
Farmer 97 (25.1 %)
Other*** 35 (9.1 %)
Income
167–541 96 (24.9 %)
542–1000 120 (31.1 %)
1001–1888 75 (19.4 %)
1889–10000 95 (24.6 %)
Other* includes Jehovah’s witnesses
Other** includes Tigrae, Wolayita and Hadiya
Other*** includes wood workers, daily laborer, house wife and students
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Table 2 Association of relapse with socio demographic characteristics (bivariate logistic regression)
Variables N Relapse No relapse P-value Crude OR 95 % CI
Sex
Male 279 71 (25.4 %) 208 (74.6 %) 0.54 1.18 0.50, 2.00
Female 107 24 (22.4 %) 83 (77.6 %) Reference
Age
18–24 79 14 (17.7 %) 65 (82.3 %) 0.16 0.62 0.39, 1.20
25–34 186 48 (25.8 %) 138 (74.2 %) Reference
35–44 82 23 (28 %) 59 (72 %) 0.70 1.12 0. 63, 2.01
45–54 28 9 (32.1 %) 19 (67.9 %) 0.48 1.36 0. 58, 3.21
55–68 11 1 (9.1 %) 10 (90.9 %) 0.24 0.29 0. 04, 2.31
Ethnicity
Oromo 239 55 (23 %) 184 (77 %) Reference
Amhara 66 20 (30.3 %) 46 (69.7 %) 0.23 1.46 0. 79, 2.66
Gurage 19 4 (21.1 %) 15 (78.9 %) 0.85 1. 89 0. 28, 2.80
Kaffa 26 4 (15.4 %) 22 (84.6 %) 0.379 0.61 0. 20, 1.84
Dawro 20 7 (35 %) 13 (65 %) 0.23 1.80 0. 69, 4.74
Yem 5 1 (20 %) 4(80 %) 0.87 0.84 0. 09, 7.64
Other* 11 4 (36.4 %) 7 (63.6 %) 0.32 1.91 0. 54, 6.77
Religion
Orthodox 97 25 (25.8 %) 72 (74.2 %) 0.79 1.08 0. 63, 1.86
Muslim 234 57 (24.4 %) 177 (75.6 %) Reference
Other** 55 13 (23.6 %) 42 (76.4 %) 0.91 0.96 0. 48, 1.92
Frequency of worship
Frequently 170 35 (20.6 %) 135 (79.4 %) Reference
Sometime 196 51 (26 %) 145 (74 %) 0.22 1.36 0.83, 2.21
Never 20 9 (45 %) 11 (55 %) 0. 02 3.16 1.21, 8.21
Marital status
Single 179 44 (24.6 %) 135 (75.4 %) 0.93 0.98 0. 61, 1.57
Married 188 47 (25 %) 141 (75 %) Reference
Divorced 11 1 (9.1 %) 10 (90.9 %) 0.26 0.30 0. 04, 2.41
Separated/widowed 8 3 (37.5 %) 5 (62.5 %) 0.43 1.80 0. 41, 7.82
Educational status
Illiterate 50 12 (24 %) 38 (76 %) 0.65 1.19 0. 56, 2.50
Primary 176 37 (21 %) 139 (79 %) Reference
Secondary 96 19 (19.8 %) 77 (80.2 %) 0.81 0.93 0. 50, 1.72
tertiary 64 27 (42.2 %) 37 (57.8 %) 0.001 2.74 1.48, 5.07
Occupation
Unemployed 112 25 (22.3 %) 87 (77.7 %) Reference
Government employee 87 29 (33.3 %) 58 (66.7 %) 0.09 1.74 0. 93, 3.27
Merchant 26 4 (15.4 %) 22 (84.6 %) 0.44 0.63 0.20, 2.01
Farmer 97 23 (23.7 %) 74 (76.3 %) 0.81 1.08 0. 57, 2.06
Other*** 64 14 (21.9 %) 50 (78.1 %) 0.95 0.97 0.46, 2.04
Income
167–541 96 21 (21.9 %) 75 (78.1 %) 0.73 1.12 0.58, 2.17
542–1000 120 24 (20 %) 96 (80 %) Reference
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Variables with p-value < 0.05 in the multivariate analyses
were considered significant predictors of relapse.
Results
Paricipants characteristics
A total of 386 participants were approached to participate
in the study and all of them agreed to participante with
the response rate of 100 %. Nearly 72.3 % (n = 279) of par-
ticipants were males; 61.9 % (n = 239) were Oromo in eth-
nic origin. Of the total participants, nearly 61 % (n = 234)
were Islamic religion followers followed by Orthodox
Christians (25.1 %; n = 97). Out of the total partici-
pants of this study, 73.5 % (n = 280) were diagnosed
as cases of schizophrenia. The mean age of the par-
ticpants was 31.49 ± SD 9.36 years ranging from 18 to
68 and 48.2 % (n = 186) were between the ages of
25–34 years. Nearly, half of the the study participants
(48.7 %; n = 188) were married. Amongst the total
study participants, 29 % (n = 112) were unemployed.
The mean monthly income of the study participants
was 1446.13 ± 1291.27 Ethiopian Birr (1 USD = 20.91
ETB) (see Table 1).
Prevalence of relapse among patients with psychotic
disorders
Out of the total participants, 24.6 % (n = 95) had at least
one relapse or reoccurrence of psychotic symptoms within
the past 6 months; 14.8 % (n = 57) had only one relapse;
9.8 % (n = 38) had more than one relapse. Prevalence of
relapse among male participants was 25.4 % (n = 71).
Nearly one fourth (25.8 %, n = 48) of patients with relapse
were found among the patients in the age group of
25–34 years (see Table 2).
Nearly one-fourth of participants who were diagnosed
as having schizophrenia (25 % n = 70), schizophreniform
and schizoaffective disorders (25.5 %, n = 13) had psych-
otic relapse (Table 3).
Factors associated with relapse
Out of the total particpants, only 7.7 % (n = 30) reported
that they were non-compliant to their medication. Of
these, 50 % (n = 15) had relapse. Some of the reasons re-
ported by participants for becoming non-compliant to
their medication were forgetting to take medications
(8 %, n = 30), feeling better (11.7 %, n = 45) and worsen-
ing of the symptoms (9.3 %, n = 36). Out of the total par-
ticpants, 75.4 % (n = 291) reported that, medication
makes them feel tired (see Table 4). Abnormal involun-
tary movement scale (AIMS) was done for all partici-
pants and 41 % (n = 157) of the participants had scored
above the mean (2.99 ± SD 4.26) score. Out of patients
who experienced medication side effects, 29.3 % (n = 46)
reported having had a relapse (see Table 4).
Additionally, nearly half, 49 % (n = 173) of the total
participants were found to drink alcohol. Of this, 7 %
(n = 27) had alcohol use disorders. Among patients
with alcohol use disorders, 40.7 % (n = 11) were identified
as having a psychotic relapse. Out of this patients, 81.5 %
(n = 22) were diagnosed with schizophrenia (see Table 5).
The prevalence of relapse among patients with low so-
cial support was 26.8 % (n = 70) (see Table 6). Nearly
29 % (n = 61) and 27.7 % (n = 41) of participants who
sought religious and traditional support before coming
to the hospital had relapse respectively (see Table 6).
Among patients having comordbid psychiatric illnesses,
30 (33.7 %) of them had psychotic relapse. In the
Table 2 Association of relapse with socio demographic characteristics (bivariate logistic regression) (Continued)
1001–1888 75 26 (34.7 %) 49 (65.3 %) 0.02 2.12 1.11, 4.08
1889–10000 95 24 (25.3 %) 71 (74.7 %) 0.36 1.35 0.71, 2.57
Living condition
Alone 32 5(15.6 %) 27(84.4 %) Reference
With family 339 88(26 %) 251(74 %) 0.20 0.53 0.20, 1.41
With relative 15 2(13.3 %) 13(86.7 %) 0.28 0.44 0.10, 1.98
Other* includes Wolayita, Tigrie and Hadiya
Other**includes Protestant, Catholic and Jehovah witness
Other*** includes wood workers, daily laborers, house wives and students
Table 3 Association of relapse with the type of psychotic diagnosis (bivariate logistic regression)
Variables N Relapse No relapse P-value Crude OR 95 % CI
Diagnosis
Schizophrenia 280 70 (25 %) 210 (75 %) 0.62 1.19 0.60, 2.39
Schizophreniform and schizoaffective 51 13 (25.5 %) 38 (74.5 %) 0.66 1.23 0.50, 3.01
Brief psychotic 55 12 (21.8 %) 43 (78.2 %) Reference
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bivariate analyses, having comorbid psychiatric illness
was significantly associated with relapse (Table 7).
After adjusting for potential confounders using multi-
variate logistic regression anlaysis, living with family com-
pared to living alone, being compliant to medication high
score social support and seeking religious help were statis-
tically associated with reduced odds of developing psych-
otic relapse. The odds of developing psychotic relapse
among patients living with family was 72 % lower than
that of patients living alone (aOR = 0.28, 95 % CI = 0.08,
0.93). The odds of developing psychotic relapse among
patients compliant to medication was 69 % lower than
that of patients who were not compliant to medications
(aOR = 0.31, 95 % CI = 0.12, 0.80). The odds of developing
psychotic relapse among patients having high score
on social support score was 48 % lower than that of
patients who were compliant to medications (aOR = 0.52,
95 % CI = 0.28, 0.95). The odds of developing psychotic re-
lapse among patients reporting to have sought religious
support was 45 % lower than that of patients who have
not sought religious support (aOR = 0.55, 95 % CI = 0.31,
0.96) (see Table 8).
On the other hand, the odds of developing psychotic
relapse among participants who have experienced medi-
cation side effects was 1.83 times higher when compared
to those who have never experienced medication side
effects (aOR = 1.83, 95 % CI = 1.01, 3.31) (see Table 8).
Discussions
In this study, about one-third of the study participants
were identified to have relapse. This finding was in
agreement with a Canadian study (35.7 %) [37]. How-
ever, the finding is lower than study findings from a
community cohort study conducted in Butajira Ethiopia,
(54 %) [38]. This difference could be due to the differ-
ence in the type of the study. While our study was
hospital-based, the study conducted in Butajira was a
community-based study. This finding may be expected
because psychotic patients in the community might not
have been on therapy provided in modern health intitu-
tions. In addition, the relapse rate in or study was lower
than the study conducted in Hong Kong (48.1 %) [39].
In the current study, lower relapse was associated with
living with family member compared to living alone,
seeking religious support, high score on social support,
and compliance to medication. This was in agreement
with the findings of the studies conducted in South
Africa and Hong Kong [39, 40]. The odds of having re-
lapse among participants who live with family was 72 %
lower than that of patients who live alone. This could be
due to the reason that, when patients live alone; they do
not have anyone to encourage or remind them to take
their medication properly and attend their follow-up
regularly. This is in agreement with the study done in
Spain, which indicated that cohabitation with other
Table 4 Association of psychotic relapse with medication related factors (bivariate logistic regression)
Variables N Relapse No relapse P-value Crude OR 95 % CI
MARSa
Compliant 356 80 (22.5 %) 276 (77.5 %) 0.001 0.29 0.14, 0.62
Non-compliant 30 15 (50 %) 15 (50 %) Reference
AIMSb
Below mean 229 49 (21.4 %) 180 (78.6 %) Reference
Above mean 157 46 (29.3 %) 111 (70.7 %) 0.08 1.52 0.96, 2.43
aMARS medication adherence rating scale
bAIMS abnormal involuntary movment scale
Table 5 Association of relapse with substance related factors (bivariate logistic regression)
Variables N Relapse No relapse P-value Crude OR 95 % CI
CAGEa
No problem problem drinking 359 84 (23.4 %) 275 (76.6 %) Reference
Problem drinking 27 11 (40.7 %) 16 (59.3 %) 0.05 2.25 1.01, 5.04
DASTb
No 213 43 (20.2 %) 170 (79.8 %) Reference
Low 33 4 (12.1 %) 29 (87.9 %) 0.28 0.55 0.18, 1.63
Moderate 114 36 (31.6 %) 78 (68.4 %) 0.02 1.83 1.09, 3.06
Substantial 26 12 (46.2 %) 14 (53.8 %) 0.004 3.39 1.46, 7.85
aCudown, annoyed, guilty and eye opener
bDrug abuse screening test
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people improves compliance to medication because rela-
tives could serve as supervisors [41].
In this study, the odds of developing psychotic relapse
among patients who were compliant to their medication
was 69 % lower when compared to the odds among
non-compliant patients. This finding is in agreement
with the studies conducted in Norway and USA [11, 42].
This underscores the importance of interventions that
improve compliance to medication as part of the mea-
sures taken to reduce psychotic relapse. Further studies
are needed to identify interventions that are effective
and feasible in the context for improving compliance to
medication.
In the current study the prevalence of relapse among
patients with medication side effects was 29.3 % (n = 46).
An Indian study reported a relapse rate of 37.5 % among
patients with medication side effects [43]. This difference
could be due to difference in the instrument (AIMS vs.
clinical interview). We used AIMS, while the Indian study
used clinical interview. The instrument we used for asses-
sing medication side effect (AIMS) assesses only extra
pyramidal side effects, and hence, it might have underesti-
mated the magnitude of medication side effects.
In the current study, the odds of developing relapse
among patients who have experienced medication side
effects was 1.83 times higher when compared to that of
patients who have never experienced medication side ef-
fects. This underscores the importance of emphasizing
detection and treatment of medication side effects
among psychotic patients. The use of antipsychotic
drugs that are asssociated with less side effects may be
considered. A meta-analysis has shown that risperidone
use was associated with less side effects compared to halo-
peridol [44]. In addition, it is essential to link mentally ill
persons to NGOs (non-governmental oraganizations) that
support recovery and rehablitation of persons with mental
disorders. Moreover, developing and strengthening cultur-
ally acceptable community rehabilitation intervention and
recovery-oriented services that help to develop the skills
of patients in dealing with mental health problem is essen-
tial. Components such as psycho-education, family inter-
vention, relapse prevention, adherence support, stress and
anger management should be included in community
based rehabilitation interventions [45].
In the current study, the odds of having relapse among
patients who had sought religious support before coming
to the hospital was 45 % lower than that of patients who
have never sought religious support. This could be be-
cause some religious practices help patients to cope with
the illness and avoid the use of psychoactive substances
[46]. The odds of having psychotic relapse among pa-
tients who had high social support score was 48 % lower
than that of patients who had low social support score.
This finding is in agreement with one meta-analysis,
which showed that good social support was associated
with less relapse [47, 48]. This indicates the importance
of focusing on patients living alone, who have low or no
social support. Also, it is essential to arrange referral
mechanism for psycho social support services. The psych-
iatry clinic also needs to employ regular program of
psycho education and counseling. In addition, providing
Table 6 Association of relapse with social support, DUP, help seeking (bivariate logistic regression)
Variables N Relapse No relapse P-value Crude OR 95 % CI
Social support
Low score 261 70 (26.8 %) 191 (73.2 %) Reference
High score 125 25 (20 %) 100 (80 %) 0.15 0.68 0.41, 1.14
DUPa
Below mean 221 50 (22.6 %) 171 (77.4 %) Reference
Above mean 165 45 (27.3 %) 120 (72.7 %) 0.30 1.28 0. 81, 2.04
Sought support from traditional sources
Yes 148 41 (27.7 %) 107 (72.3 %) 0.27 1.31 0.82, 2.09
No 238 54 (22.7 %) 184 (77.3 %) Reference
Sought religious support
Yes 210 61 (29 %) 149 (71 %) Reference
No 176 34 (19.3 %) 142 (80.7 %) 0.03 0.59 0.36, 0.94
aDUP duration of untreated psychoses
Table 7 Association of relapse with comorbidity among the
patients (bivariate logistic regression)
Variables N Relapse No relapse P-value Crude OR 95 % CI
Comorbid psychiatric illness
Yes 89 30 (33.7 %) 59 (66.3 %) 0.02 1.82 1.08, 3.05
No 297 65 (21.9 %) 232 (78.1 %) Reference
Comorbid medical illness
Yes 24 9 (37.5 %) 15 (62.5 %) 0.14 1.93 0.81, 4.56
No 362 86 (23.8 %) 276 (76.2 %) Reference
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support for mentally ill people at the community level is
essential. Furthermore, Jimma town health office may
consider building rehabilitation centers or providing psy-
cho social support for people who have no social support.
The health office also needs collaboration with Jimma
town education office to create educational opportunities
for mentally ill individuals. To provide support for men-
tally ill people at the community level, integrating mental
health services into urban and rural health extension ser-
vices may be helpful.
Even though not statistically significant, 40.7 % (n = 11)
of patients with problem drinking had psychotic relapse.
In addition, 31.6 % (n = 36) of patients with moderate level
of khat abuse had relapse. This could be because of the
fact that patients use psychoactive substances to get relief
from the symptoms of the illness and side effects. A study
Table 8 Predictors of relapse among patients with psychotic
disorders (multivariate logistic regression)
Variables P-value Adjusted OR 95 % CI
Lower Upper
Sex
Male 0.75 0.89 0.45 1.76
Female Reference
Age
18–24 0.13 0.53 0 .24 1.20
25–34 Reference
35–44 0.57 1.22 0.62 2.42
45–54 0.45 1.49 0.53 4.14
55–68 0.25 0.26 0.03 2.63
Ethnicity
Oromo Reference
Amhara 0.81 1.10 0.50 2.45
Gurage 0.43 0.58 0.15 2.22
Kaffa 0.08 0.31 0.08 1.17
Dawro 0.33 1.87 0.54 6.49
Yem 0.76 0.67 0.02 8.58
Other* 0.66 0.65 0.09 4.56
Frequency of worship
Frequently Reference
Sometime 0.18 1.51 0.83 2.77
Never 0.05 3.64 0.99 13.34
Educational status
Illiterate 0.52 1.34 0.56 3.18
Primary Reference
Secondary 0.99 0.99 0.47 2.09
Tertiary 0.01 3.49 1.29 9.47
Occupation
Unemployed Reference
Government employee 0.99 0.99 0.35 2.84
Merchant 0.73 0.79 0.21 2.95
Farmer 0.62 1.25 0.51 3.06
Other*** 0.62 1.26 0.51 3.12
Income
167–541 0.43 1.35 0.64 2.82
542–1000 Reference
1001–1888 0.10 1.10 0.87 4.58
1889–10000 0.87 1.07 0.49 2.34
Living condition
Alone Reference
With family 0.04 0.28 0.08 0.93
With relative 0.23 0.32 0.05 2.02
Table 8 Predictors of relapse among patients with psychotic
disorders (multivariate logistic regression) (Continued)
MARSa




Above mean 0.04 1.83 1.01 3.31
CAGEc
No problem of drinking Reference
Drinking Problem 0.95 1.04 0.32 3.34
DASTd
No Reference
Low 0.48 0.64 0.19 2.19
Moderate 0.16 1.68 0.82 3.45
Substantial 0.11 2.61 0.810 8.42
Social support
Low score Reference
High score 0.04 0.52 0.28 0.95
Religious help seeking
Yes Reference
No 0.04 0.55 0.31 0.96
Comorbid psychiatric illness
Yes 0.52 0.77 0.35 1.70
No Reference
Comorbid medical illness
Yes 0.22 1.98 0.67 5.90
No Reference
aMARS: medication adherence rating scale
bAIMS abnormal involuntary movment scale
cCAGE cudown, annoyed, guilty and eye opener
dDAST drug abuse screening test
Other* includes Wolayita, Tigrie and Hadiya
Other*** includes wood workers, daily laborers, house wives and students
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conducted in Ethiopia at Ammanuel Hospital on patients
with schizophrenia showed that alcohol and khat
abuse were contributing factors for relapse of psych-
otic symptoms and re-hospitalization [15]. Another
literature review on substance mis-use and mental ill-
ness showed that alcohol use even with small amount
was associated with increase symptomatology and re-
hospitalization [13]. A study conducted in Australia
showed that substance mis-use was significantly asso-
ciated with relapse of positive symptoms [14].
Comorbidity of medical illnesses in this study on pa-
tients who had relapse was 37.5 % (n = 9). The study con-
ducted in South Africa on patients with schizophrenia
showed that 45.5 % (n = 6) of patients had comorbid med-
ical illnesses [40].
Nearly 27.3 % (n = 45) of participants who had long dur-
ation before treatment had relapse of psychotic illness. In
this study, duration of untreated psychoses (DUP) was not
significantly associated with relapse. Study conducted in
USA found that there is positive correlation between DUP
and number of relapses [18].
In this study nearly one-forth (n= 70) of respondents with
diagnosis of schizophrenia had relapse. This could be due to
the nature of the illness. Study conducted in Hong Kong on
first episode psychosis showed that the diagnosis schizo-
phrenia was associated with increased risk of relapse [39].
Our current study has used standard scales and instru-
ments such as MARS, AIMS, DAST-10, CAGE and SSQ-
6. The findings have implications for health program
design and service improvement especially for the country
and context. Our study has some limitations. First, the in-
strument we used for assessing medication side effects
(AIMS) assesses only extra pyramidal side effects. This
might have underestimated the rate of medication
side effects faced by participants. Secondly, the study
design is cross sectional in nature; hence, it was diffi-
cult to identify the cause and effect relationship be-
tween study variables.
Conclusions
In this study, about one-third of the respondents had re-
lapse. Living with family, seeking religious support, high
social support score and compliance with medication
were independently associated with reduced odds of de-
veloping psychotic relapse. Experiencing medication side
effects was associated with increased odds of developing
psychotic relapse. Clinicians need to detect and manage
medication side effects faced by the patients. Intervening
noncompliance to medication may help in preventing
psychotic relapse that may result because of non-
compliance. The linkage of patients to social and reli-
gious supports may help the patients in improving
compliance to medication and reducing psychotic re-
lapse. Moreover, developing and strenghtneing community
based rehabilitation services with components such as
psycho education, family intervention, relapse prevention,
adherence support and stress and anger management,
is needed. Further studies are needed to identify ef-
fective and feasible interventions that address compli-
ance to medication.
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